Suzhou, China, October 2026. CATUG Biotechnology will attend the 2nd World RNA-Based Therapeutics & Vaccines Summit South Korea, held in Incheon on November 10–12, 2026. Dr. Xijun Piao, Chief Technology Officer, will deliver a keynote presentation, and the company will host a booth on site to meet RNA industry partners from around the world.

About the Summit

Themed "Accelerating mRNA's Potential Across Infectious, Rare & Personalized Therapies," the summit covers advances in molecular design, delivery systems and scale-up manufacturing for mRNA, circRNA and saRNA therapeutics. It spans infectious disease, rare disease and personalized medicine.

• November 10: Pre-summit workshop day on drug delivery and manufacturing
• November 11–12: Main conference and scientific poster sessions

The full agenda is available at worldrna-kr.com.

Keynote Presentation

• Title: Integrated CMC Solutions for Diverse mRNA-LNP Programs
• Speaker: Dr. Xijun Piao, Chief Technology Officer, CATUG Biotechnology
• Time: Wednesday, November 11, 2026, 15:30 (local time)

As RNA pipelines move into the clinic, the industry's focus is shifting from technical feasibility to process robustness and reproducibility. Dr. Piao will walk through the end-to-end workflow of mRNA-LNP programs from development to manufacturing. He will cover process integration across plasmid, in vitro transcription (IVT), LNP formulation and aseptic fill-finish. He will also discuss key CMC considerations and timeline planning ahead of IND filing, and introduce CATUG's integrated services from early research to GMP manufacturing.

CATUG operates GMP facilities in Suzhou and Wuhan, where a single quality system connects plasmid, RNA drug substance, LNP/tLNP formulation and aseptic fill-finish. Its RNA manufacturing scale ranges from mg to 100 g. To date, CATUG has completed single-batch GMP production of more than 45 g of mRNA and more than 4 g of circRNA-tLNP. It has also delivered GMP clinical materials for multivalent circRNA-LNP, personalized cancer vaccine (PCV) and in vivo CAR-T programs. A newly added lyophilization line further strengthens CATUG's formulation stability capabilities.

Global Footprint

Since its founding in 2021, CATUG has served more than 100 overseas clients across more than 25 countries and regions. Key milestones:

• 2022: U.S. subsidiary established
• 2023: First overseas project delivered
• 2024: Swiss subsidiary established
• 2025: Suzhou GMP facility passed an EU QP audit
• 2026: Asia-Pacific Innovation Center opened at Hong Kong Science Park; international R&D center agreement signed with Wuxi National Hi-Tech District; IMAPAC Asia-Pacific RNA Excellence Award received

Meet Us in Incheon

CATUG invites partners developing mRNA, circRNA and saRNA therapeutics to visit its booth to discuss LNP/tLNP formulation development, pre-IND material manufacturing and CMC strategy. To schedule a meeting, contact BD@catugbio.com.

Presentation timing is subject to the organizer's final agenda.